284 related articles for article (PubMed ID: 25999707)
1. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.
Zhang JQ; Zhang JQ; Liu H; Zhao ZH; Fang LZ; Liu L; Fu WP; Shu JK; Feng JG; Dai LM
Int J Chron Obstruct Pulmon Dis; 2015; 10():917-23. PubMed ID: 25999707
[TBL] [Abstract][Full Text] [Related]
2. Effect of oral N-acetylcysteine on COPD patients with microsatellite polymorphism in the heme oxygenase-1 gene promoter.
Zhang JQ; Zhang JQ; Fang LZ; Liu L; Fu WP; Dai LM
Drug Des Devel Ther; 2015; 9():6379-87. PubMed ID: 26674585
[TBL] [Abstract][Full Text] [Related]
3. [Study on the relationship between EPHX1 gene polymorphism and antioxidant capacity in patients with chronic obstructive pulmonary disease].
Luo Y; Dai LM; Jia M; Zhao ZH; Hu CM; Qi WY; Zhang JQ
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):760-764. PubMed ID: 31594110
[No Abstract] [Full Text] [Related]
4. Microsomal epoxide hydrolase is not associated with COPD in a community-based sample.
Matheson MC; Raven J; Walters EH; Abramson MJ; Ellis JA
Hum Biol; 2006 Dec; 78(6):705-17. PubMed ID: 17564249
[TBL] [Abstract][Full Text] [Related]
5. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
Calverley PM; Postma DS; Anzueto AR; Make BJ; Eriksson G; Peterson S; Jenkins CR
Int J Chron Obstruct Pulmon Dis; 2016; 11():381-90. PubMed ID: 26952309
[TBL] [Abstract][Full Text] [Related]
6. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
7. Differential changes in quality of life components over 5 years in chronic obstructive pulmonary disease patients.
Nagai K; Makita H; Suzuki M; Shimizu K; Konno S; Ito YM; Nishimura M;
Int J Chron Obstruct Pulmon Dis; 2015; 10():745-57. PubMed ID: 25914531
[TBL] [Abstract][Full Text] [Related]
8. Association between polymorphisms of microsomal epoxide hydrolase and COPD: results from meta-analyses.
Hu G; Shi Z; Hu J; Zou G; Peng G; Ran P
Respirology; 2008 Nov; 13(6):837-50. PubMed ID: 18811882
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of microsomal epoxide hydrolase is associated with chronic obstructive pulmonary disease and bronchodilator response.
Chen CZ; Wang RH; Lee CH; Lin CC; Chang HY; Hsiue TR
J Formos Med Assoc; 2011 Nov; 110(11):685-9. PubMed ID: 22118311
[TBL] [Abstract][Full Text] [Related]
11. The COPD assessment test and St George's Respiratory Questionnaire: are they equivalent in subjects with COPD?
Morishita-Katsu M; Nishimura K; Taniguchi H; Kimura T; Kondoh Y; Kataoka K; Ogawa T; Watanabe F; Arizono S; Nishiyama O; Nakayasu K; Imaizumi K; Hasegawa Y
Int J Chron Obstruct Pulmon Dis; 2016; 11():1543-51. PubMed ID: 27462150
[TBL] [Abstract][Full Text] [Related]
12. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
13. EPHX1 polymorphisms, COPD and asthma in 47,000 individuals and in meta-analysis.
Lee J; Nordestgaard BG; Dahl M
Eur Respir J; 2011 Jan; 37(1):18-25. PubMed ID: 20516053
[TBL] [Abstract][Full Text] [Related]
14. Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.
Manoharan A; Morrison AE; Lipworth BJ
Lung; 2016 Apr; 194(2):259-66. PubMed ID: 26758884
[TBL] [Abstract][Full Text] [Related]
15. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
Tse HN; Raiteri L; Wong KY; Yee KS; Ng LY; Wai KY; Loo CK; Chan MH
Chest; 2013 Jul; 144(1):106-118. PubMed ID: 23348146
[TBL] [Abstract][Full Text] [Related]
16. Microsomal epoxide hydrolase gene polymorphisms and susceptibility to chronic obstructive pulmonary disease in the Tunisian population.
Lakhdar R; Denden S; Knani J; Leban N; Daimi H; Hassine M; Lefranc G; Chibani JB; Khelil AH
Genet Test Mol Biomarkers; 2010 Dec; 14(6):857-63. PubMed ID: 20932192
[TBL] [Abstract][Full Text] [Related]
17. Do frequent moderate exacerbations contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers?
Dreyse J; Díaz O; Repetto PB; Morales A; Saldías F; Lisboa C
Int J Chron Obstruct Pulmon Dis; 2015; 10():525-33. PubMed ID: 25792820
[TBL] [Abstract][Full Text] [Related]
18. EPOXID HYDROLASE SINGLE GENE POLYMORPHISM (RS1051740) AND SEVERITY OF CHRONIC OBSTRUCTIVE DISEASE.
Antonova I; Gridnyev O; Galchinskaya V
Wiad Lek; 2022; 75(11 pt 2):2779-2784. PubMed ID: 36591768
[TBL] [Abstract][Full Text] [Related]
19. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
